Interferon (IFN) signaling plays a crucial role in autoimmunity. Genetic variation in interferon regulatory factor 5 (IRF5), a major regulator of the type I interferon induction, has been associated with risk of developing several autoimmune diseases. In the current study we aimed to evaluate whether three sets of correlated IRF5 genetic variants, independently associated with SLE and with different functional roles, are involved in uveitis susceptibility and its clinical subphenotypes.
Three IRF5 polymorphisms, rs2004640, rs2070197 and rs10954213, representative of each group, were genotyped using TaqMan® allelic discrimination assays in a total of 263 non-anterior uveitis patients and 724 healthy controls of Spanish origin.
A clear association between two of the three analyzed genetic variants, rs2004640 and rs10954213, and the absence of macular edema was observed in the case/control analysis (PFDR=5.07E-03, OR=1.48, CI 95%=1.14-1.92 and PFDR=3.37E-03, OR=1.54, CI 95%=1.19-2.01, respectively). Consistently, the subphenotype analysis accordingly with the presence/absence of this clinical condition also reached statistical significance (rs2004640: P=0.037, OR=0.69, CI 95%=0.48-0.98; rs10954213: P=0.030, OR=0.67, CI 95%=0.47-0.96), thus suggesting that both IRF5 genetic variants are specifically associated with the lack of macular edema in uveitis patients.
Our results clearly showed for the first time that two functional genetic variants of IRF5 may play a role in the development of macular edema in non-anterior uveitis patients. Identifying genetic markers for macular edema could lead to the possibility of developing novel treatments or preventive therapies.
Citation: Márquez A, Cénit MC, Cordero-Coma M, Ortego-Centeno N, Adán A, Fonollosa A, et al. (2013) Two Functional Variants of IRF5 Influence the Development of Macular Edema in Patients with Non-Anterior Uveitis. PLoS ONE 8(10): e76777. https://doi.org/10.1371/journal.pone.0076777
Editor: James T. Rosenbaum, Oregon Health & Science University, United States of America
Received: July 11, 2013; Accepted: August 27, 2013; Published: October 7, 2013
Copyright: © 2013 Márquez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Uveitis is a general term used to describe a diverse group of clinical entities with a variety of etiologies. It is one of the leading causes of blindness worldwide accounting for about 10% of the severe visual handicap [1,2]. Uveitis patients are frequently classified according to the anatomical location of the inflammation into anterior uveitis (AU), the most common form, intermediate uveitis (IU), posterior uveitis (PU) and panuveitis or also called diffuse uveitis (PAN) .
Non-infectious uveitis is believed to have an autoimmune component [4,5]. Studies in human and animal models have suggested that autoimmune uveitis presents a complex inheritance pattern with multiple genetic and environmental factors involved in the appearance and progression of this condition [6,7].
The genetic predisposition to develop uveitis has long been investigated. The association between certain HLA alleles, particularly HLA-A29 in birdshot chorioretinopathy and HLA-B27 in anterior uveitis, is well known [8,9]. However, HLA accounts for only a small part of the genetic predisposition to immune-mediated uveitis.
Outside the HLA region, several genes have been proposed to play a role in the development of diseases involving uveitis; however only a few loci have been confirmed as genetic risk factors, such as IL23R/IL12RB2 or IL10 in Behçet’s disease (BD) [10,11], and, currently, the overall underlying mechanisms of the uveitis induction remain unclear.
The type I interferons (IFNs) are signalling molecules involved in both innate and adaptive immunity. The IFN pathway has been postulated to play a crucial role in autoimmune diseases. Specifically, several single nucleotide polymorphisms (SNPs) on the interferon regulatory factor 5 (IRF5) gene, a major regulator of the type I IFN induction and critical for the production of pro-inflammatory cytokines, have been associated with different autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, systemic sclerosis, inflammatory bowel disease and Sjöegren’s syndrome [12–17]. In SLE, three independent sets of correlated IRF5 variants that provide statistically independent evidence for association have been reported . Polymorphisms in each of these groups seem to have different functional consequences such as alteration of a consensus splice donor site allowing expression of an alternative exon 1, creation of an early polyadenylation site that leads to a shorter isoform and alteration of the protein stability.
It has been suggested that autoimmune uveitis shares different genetic factors with other autoimmune disorders . The aim of our study was to analyze three SNPs, representative of each group of variants independently associated with SLE, in order to explore the role of IRF5 in uveitis susceptibility and its clinical subgroups.
Patients and Methods
A subject’s written consent was obtained according to the declaration of Helsinki, and the design of the work was approved by the Ethics Committee of Granada (Spain). The Ethics Committees of the Hospital de León (León), Hospital Universitario Príncipe de Asturias (Alcalá de Henares), Hospital de Cruces (Bilbao), Hospital Clinic (Barcelona), Hospital Clínico San Carlos (Madrid), Hospital Marqués de Valdecilla (Santander), Hospital Universitario La Fe (Valencia), Hospital Clínico San Cecilio (Granada) and Hospital Carlos Haya (Málaga) also approved the study.
A total of 263 patients with non-infectious uveitis, excluding the exclusively anterior uveitis forms as well as uveitis associated with systemic immune-mediated diseases except Vogt-Koyanagi-Harada syndrome, and 724 ethnically matched healthy controls, all of them from Spain, were included in the present study.
In addition, to examine whether the selected SNPs might influence the different clinical manifestations of the disease, uveitis patients were subdivided according to different characteristics included in Table 1. The intraocular inflammation seen in patients included intermediate uveitis (24.0%), posterior uveitis (51.7%), and panuveitis (24.3%). Macular edema was diagnosed by biomicroscopy and optical coherence tomography (Cirrus HD-OCT, Carl Zeiss Meditec, Inc). Scans were obtained using the 512 x 128 scan pattern. Fluorescein angiography (FA) was performed to rule out macular edema in doubtful cases. Macular edema was defined as a macular thickness greater than 250 µm with the presence of intraretinal cysts demonstrated by OCT , and/or the presence of retinal angiographic leakage in the central macula area for those patients in which FA was performed.
|General characteristics of uveitis patients||Uveitis (n=263)||Controls (n=724)|
|Female (%)||146 (55.5)||481 (66.4)|
|Age (mean ± SD)||48.3 ± 16.4||49.1 ± 12.5|
|Intermediate Uveitis (%)||63 (24.0)||-|
|Posterior Uveitis (%)||136 (51.7)||-|
|Panuveitis (%)||64 (24.3)||-|
|Bilaterality (%)||206 (78.3)||-|
|Vitritis (%)||177 (67.3)||-|
|Macular edema (%)||121 (46.0)||-|
|Retinal vasculitis (%)||116 (44.1)||-|
|Choroidal neovascularization (%)||25 (9.51)||-|
Genomic DNA was extracted from peripheral white blood cells and saliva, using standard procedures. Three SNPs, rs2004640, rs2070197 and rs10954213, located on the IRF5 gene, were genotyped using a pre-designed TaqMan® allelic discrimination assay in a 7900HT Real-Time polymerase chain reaction (PCR) System from Applied Biosystems (Foster City, CA, USA). The genotype call rate was 99% for the tested genetic variants. In addition, randomly selected samples were genotyped twice to verify the genotyping accuracy. The 99% of the genotypes were identical.
We carried out a case-control study using Plink (v1.07) (http://pngu.mgh.harvard.edu/purcell/plink/). The genotype, allele and carrier frequencies were compared between patients, subgroup of patients and controls applying χ2 test and/or Fisher’s exact test when necessary (when the expected frequencies were lower than 5). Odds ratios (OR) and 95% confidence intervals (CI) were obtained according to Woolf’s method. Since different polymorphisms were analyzed in the current study, the Benjamini & Hochberg (1995) step-up false discovery rate (FDR) control correction for multiple testing was applied to the P-values. P-values after FDR correction lower than 0.05 were considered as statistically significant.
Dependency of association between the studied genetic variants was determined by conditional logistic regression analysis implemented in PLINK, and the allelic combinations were tested using PLINK and Haploview (V. 4.2).
To analyze whether allelic combinations would better explain the possible association than the genetic variants independently, we compared the goodness of fit of both models using PLINK. For that purpose, we calculated the deviance (defined as -2 x the log likelihood), which follows a χ2 distribution, to assess the significance of the improvement in fit. If statistically significant differences in the improvement of fit were observed when the haplotype effect was considered, we assumed that this model was more informative explaining the putative association.
No statistically significant deviation from Hardy-Weinberg equilibrium (P> 0.01) was observed for every SNP in the controls set and the frequencies of the analyzed SNPs were in agreement with the data of the HapMap project.
As shown in Table 2, when genotype and allelic frequencies were compared between uveitis patients and controls, a trend of association of rs2004640 and rs10954213 with uveitis was found. However, the stratification of uveitis patients accordingly with the presence/absence of the different clinical characteristics, showed in Table 1, evidenced that these signals were due to a specific association with patients without macular edema (rs2004640: PFDR=5.07E-03, OR=1.48, CI 95%=1.14-1.92; rs10954213: PFDR=3.37E-03, OR=1.54, CI 95%=1.19-2.01). Consistently, statistically significant differences were observed when comparing uveitis patients with and without this trait (rs2004640: P=0.037, OR=0.69, CI 95%=0.48-0.98; rs10954213: P=0.030, OR=0.67, CI 95%=0.47-0.96) (Table 2).
|Genotype, N (%)||Allele test|
|SNP||1/2||Subgroup (N)||1/1||1/2||2/2||MAF (%)||P-value*||PFDR**||OR [CI 95%]***|
|rs2004640 a||G/T||Controls (n=723)||135 (18.67)||356 (49.24)||232 (32.09)||43.29|
|Uveitis (n=258)||58 (22.48)||132 (51.16)||68 (26.36)||48.06||0.0613||0.0919||1.21 [0.99-1.48]|
|With edema (n=119)||25 (21.01)||54 (45.38)||40 (33.61)||43.70||0.9068||0.9068||1.02 [0.77-1.34]|
|Without edema (n=134)||32 (23.88)||78 (58.21)||24 (17.91)||52.99||3.38E-03||5.07E-03||1.48 [1.14-1.92]|
|rs2070197 b||C/T||Controls (n=723)||9 (1.24)||113 (15.63)||601 (83.13)||9.06|
|Uveitis (n=261)||1 (0.38)||35 (13.41)||225 (86.21)||7.09||0.1671||0.1671||0.77 [0.52-1.12]|
|With edema (n=120)||0 (0.00)||17 (14.17)||103 (85.83)||7.08||0.3164||0.9068||0.77 [0.45-1.29]|
|Without edema (n=136)||1 (0.74)||17 (12.50)||118 (86.76)||6.99||0.2662||0.2662||0.75 [0.46-1.24]|
|rs10954213 c||G/A||Controls (n=723)||88 (12.17)||323 (44.67)||312 (43.15)||34.51|
|Uveitis (n=261)||48 (18.39)||112 (42.91)||101 (38.70)||39.85||0.0293||0.0880||1.26 [1.02-1.55]|
|With edema (n=120)||19 (15.83)||47 (39.17)||54 (45.00)||35.42||0.7843||0.9068||1.04 [0.78-1.39]|
|Without edema (n=136)||29 (21.32)||64 (47.06)||43 (31.62)||44.85||1.12E-03||3.37E-03||1.54 [1.19-2.01]|
Conditional logistic regression
Since an independent effect of the two associated SNPs has been reported, we decided to perform pairwise conditioning analysis to test whether there could be any dependence among them (Table S1). However, both SNPs lost the statistical significance after conditioning to each other.
We also carried out the allelic combination analysis for studied IRF5 polymorphisms (Figure S1 shows the linkage disequilibrium between the three analyzed polymorphisms). This analysis also showed a phenotype-specific association of IRF5 with the absence of macular edema (Table 3) but not with the global disease (data not shown). Two associated haplotypes, containing the risk and protective alleles of the two associated SNPs, were found in the comparison between patients without macular edema and controls (rs2004640*G-rs2070197*T-rs10954213*G: PFDR=0.011, OR=1.51, CI 95%=1.16-1.98; rs2004640*T-rs2070197*T-rs10954213*A: PFDR=0.020, OR=0.70, CI 95%=0.53-0.92). When patients with and without edema were compared, an association of the rs2004640*G-rs2070197*T-rs10954213*G haplotype was also evident (P=6.69E-03, OR=0.59, CI 95%=0.41-0.86).
|Without macular edema vs. controls||With vs. Without macular edema|
|Allelic combination||Freq. With edema||Freq. Without edema||Freq. Controls||P-value||PFDR||OR [95% CI]||P-value||PFDR*||OR [95% CI]|
|GTG||0.279||0.397||0.304||2.22E-03||0.011||1.51 [1.16-1.98]||6.69E-03||0.033||0.59 [0.41-0.86]|
|TTA||0.413||0.349||0.435||8.06E-03||0.020||0.70 [0.53-0.92]||0.108||0.271||1.31 [0.91-1.87]|
|GTA||0.163||0.132||0.129||0.887||0.351||1.05 [0.71-1.53]||0.451||0.375||1.27 [0.78-2.07]|
|TCA||0.071||0.070||0.091||0.281||0.351||1.00 [0.83-1.20]||0.939||0.375||1.00 [0.78-1.28]|
|TTG||0.075||0.051||0.041||0.491||0.491||1.32 [0.73-2.37]||0.375||0.375||1.47 [0.72-2.99]|
When comparing the haplotype model with the independent SNP model, we did not observe a statistically significant improvement of the goodness of fit compared to rs2004640 (without macular edema vs. controls: likelihood P-value=0.073; with vs. without macular edema: likelihood P-value=0.071) or rs10954213 (without macular edema vs. controls: likelihood P-value=0.180; with vs. without macular edema: likelihood P-value=0.061) individually.
IRF5 is member of a family of transcription factors that play a crucial role in the control of inflammatory and immune responses. Several studies have established that IRF5 is involved in the production of type I IFNs and it is critical for the production of the pro-inflammatory cytokines TNF-α, IL-12 and IL-6, following Toll-like receptor signaling . Recently the role of the type I interferon pathway in the development of autoimmunity has become increasingly important. Additionally, several genetic studies have identified IRF5 genetics variants associated with an increased risk of several autoimmune diseases [12–17].
Three groups of correlated IRF5 SNPs, designated as Groups 1, 2 and 3, independently associated with SLE and with different functional roles have been described . Group 1 includes SNPs tagging a 30-bp in-frame INDEL variant of exon 6 that alters protein stability; the association of the Group 2 SNPs seems to be explained by the T allele of rs2004640 which allows the expression of an alternative isoform 1B and is associated with significantly higher levels of IRF5 expression; and finally, the association of the Group 3 SNPs is probably due to the rs10954213 A allele that creates an early polyadenylation site leading to a higher IRF5 expression [18,22,23]. All the risk alleles of these polymorphisms segregate in a strongly associated haplotype tagged by the C allele of the rs2070197, belonging to Group 1.
In the present study we analyzed one tagging SNP of each group of independent signals, rs2004640, rs2070197 and rs10954213. No association of any of these polymorphisms with the global disease was evident, however, our results clearly showed that two of the three analyzed variants, rs2004640 and rs10954213, influence the development of macular edema in uveitis patients, supported by a high statistical power; as shown in Table S2, the statistical power of our study is higher than 80% to detect the observed odds ratio (OR=1.5). It was not possible to determine whether these two genetic variants represent independent signals in uveitis, as previously reported in other autoimmune diseases. The fact that the conditional logistic regression analysis showed no conclusive results could be due to a reduced statistical power. On the other hand, no additive effect among these two functional IRF5 polymorphisms was evident, since the model considering a haplotype effect did not better explain the observed association than that of the independent SNPs. Nevertheless, this should be taken with caution, because a lack of statistical power could also represent a limitation in this analysis; indeed, the comparison of the goodness of fit of both models almost reached statistical significance. Regarding rs2070197, we found no evidence of association with non-anterior uveitis or clinical subphenotypes. However, the statistical power of this analysis was compromised due to the low frequency of the minor allele and, therefore, weak effects were hardly detected.
Opposed to our results, a previous study performed in Han Chinese population  failed to show association between two IRF5 polymorphisms, rs2280714 and rs752637, and BD. It is important to note that both belong to Group 3 and are highly correlated with rs10954213 (r2>0.8); therefore, these genetic variants have been covered in our study.
In uveitis, macular edema forms a major cause of visual impairment and blindness . The exact pathogenesis of this trait in patients with uveitis is not clear but the cause of pathologic fluid retention and protein accumulation within the retina seems to be a disruption of the blood retinal barrier (BRB) formed by the zonulae occludentes and adhaerentes of the retinal pigment epithelial cells (outer barrier) and endothelial cells of retinal vessels (inner barrier). Intraocular inflammation may lead to the disturbance of the BRB via the release of local inflammatory mediators. It has been shown that IL-6 may indirectly cause an increase of vascular permeability and angiogenesis by inducing the expression of VEGF (vascular endothelial growth factor), a major known factor in angiogenesis and vasopermeability in the eye . Elevated levels of intraocular IL-6 and TNF-α, whose expression is upregulated by IRF5, have been reported in patients with intermediate uveitis, especially in those with macular edema .
Our data are consistent with these findings. Taking into account that the frequency of the rs2004640*T and rs10954213*A alleles is lower in the group of patients without macular edema than in those presenting this trait, it could be speculated that patients without edema present decreased IRF5 levels and, therefore, lower levels of inflammatory cytokines involved in the development of macular edema, including TNF- α and IL-6.
Interestingly, several studies have reported that the treatment with type I IFNs (IFN-β-1 and IFN-α-2a) leads to complete or partial resorption of macular edema in a high percentage of uveitis patients [27,28], thus supporting the key role of the IFN signaling in this trait.
In conclusion, we show for a first time that two genetic variants within the IRF5 region influence the macular edema development in patients with non-anterior uveitis. Functional studies will be necessary to clarify the implication of the IRF5 alleles in the pathophysiology of this trait.
Linkage disequilibrium between the analyzed IRF5 genetic variants.
Conditional logistic regression analysis for rs2004640 and rs10954213 IRF5 genetic variants.
The authors thank Sofía Vargas, Sonia García and Gema Robledo (from Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Spain) for their excellent technical assistance, and all the patients and healthy controls for kindly accepting their essential collaboration. Banco Nacional de ADN (University of Salamanca, Spain) and Biobanco Vasco para la Investigación (Fundación Vasca de Innovación e Investigación Sanitarias, Bizkaia, Spain) are thanked for supplying part of the samples.
Conceived and designed the experiments: AM M. Carmen Cénit JM. Performed the experiments: AM M. Carmen Cénit. Analyzed the data: AM M. Carmen Cénit. Contributed reagents/materials/analysis tools: M. Cordero-Coma NO-C AA AF DDV EP RB JC MD-LL EDR MJDR JLGS JA JMM-V VLL MBG-E JM. Wrote the manuscript: AM. Reviewed and approved the manuscript: M. Carmen Cénit M. Cordero-Coma NO-C AA AF DDV EP RB JC MD-LL EDR MJDR JLGS JA JMM-V VLL MBG-E JM. Interpreted data: AM M. Carmen Cénit M. Cordero-Coma NO-C AA AF DDV EP RB JC MD-LL EDR MJDR JLGS JA JMM-V VLL MBG-E JM.
- 1. Nussenblatt RB (1990) The natural history of uveitis. Int Ophthalmol 14: 303-308. doi:10.1007/BF00163549. PubMed: 2249907.
- 2. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80: 332-336. doi:10.1136/bjo.80.4.332. PubMed: 8703885.
- 3. Deschenes J, Murray PI, Rao NA, Nussenblatt RB (2008) International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm 16: 1-2. doi:10.1080/09273940801899822. PubMed: 18379933.
- 4. Caspi RR (2002) Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21: 197-208. doi:10.1080/08830180212063. PubMed: 12424843.
- 5. Commodaro AG, Bueno V, Belfort R Jr., Rizzo LV (2011) Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation. Autoimmun Rev 10: 205-209. doi:10.1016/j.autrev.2010.10.002. PubMed: 20959149.
- 6. Martin TM, Rosenbaum JT (2005) Genetics in uveitis. Int Ophthalmol Clin 45: 15-30. doi:10.1097/01.iio.0000155939.83083.dd. PubMed: 15791155.
- 7. Pennesi G, Caspi RR (2002) Genetic control of susceptibility in clinical and experimental uveitis. Int Rev Immunol 21: 67-88. doi:10.1080/08830180212059. PubMed: 12424837.
- 8. Brewerton DA, Caffrey M, Nicholls A, Walters D, James DC (1973) Acute anterior uveitis and HL-A 27. Lancet 302: 994-996. doi:10.1016/S0140-6736(73)91090-8. PubMed: 4127279.
- 9. LeHoang P, Ozdemir N, Benhamou A, Tabary T, Edelson C et al. (1992) HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol 113: 33-35. PubMed: 1728143.
- 10. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T et al. (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet 42: 703-706. doi:10.1038/ng.624. PubMed: 20622879.
- 11. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N et al. (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. Nat Genet 42: 698-702. doi:10.1038/ng.625. PubMed: 20622878.
- 12. Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S et al. (2007) An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 16: 3008-3016. doi:10.1093/hmg/ddm259. PubMed: 17881657.
- 13. Dieudé P, Guedj M, Wipff J, Avouac J, Fajardy I et al. (2009) Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 60: 225-233. doi:10.1002/art.24183. PubMed: 19116937.
- 14. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM et al. (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38: 550-555. doi:10.1038/ng1782. PubMed: 16642019.
- 15. Han SW, Lee WK, Kwon KT, Lee BK, Nam EJ et al. (2009) Association of polymorphisms in interferon regulatory factor 5 gene with rheumatoid arthritis: a metaanalysis. J Rheumatol 36: 693-697. doi:10.3899/jrheum.081054. PubMed: 19228650.
- 16. Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L et al. (2008) Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 45: 362-369. doi:10.1136/jmg.2007.055012. PubMed: 18285424.
- 17. Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E et al. (2007) Association of an IRF5 gene functional polymorphism with Sjogren’s syndrome. Arthritis Rheum 56: 3989-3994. doi:10.1002/art.23142. PubMed: 18050197.
- 18. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR et al. (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 104: 6758-6763. doi:10.1073/pnas.0701266104. PubMed: 17412832.
- 19. Mattapallil MJ, Sahin A, Silver PB, Sun SH, Chan CC et al. (2008) Common genetic determinants of uveitis shared with other autoimmune disorders. J Immunol 180: 6751-6759. PubMed: 18453595.
- 20. Forooghian F, Yeh S, Faia LJ, Nussenblatt RB (2009) Uveitic foveal atrophy: clinical features and associations. Arch Ophthalmol 127: 179-186. doi:10.1001/archophthalmol.2008.564. PubMed: 19204236.
- 21. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW et al. (2007) Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci U S A 104: 3402-3407. doi:10.1073/pnas.0611559104. PubMed: 17360658.
- 22. Cunninghame Graham DS, Manku H, Wagner S, Reid J, Timms K et al. (2007) Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 16: 579-591. PubMed: 17189288.
- 23. Löfgren SE, Yin H, Delgado-Vega AM, Sanchez E, Lewén S et al. (2010) Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells. J Rheumatol 37: 574-578. doi:10.3899/jrheum.090440. PubMed: 20080916.
- 24. Li H, Yang P, Jiang Z, Hou S, Xie L (2009) Lack of association of two polymorphisms of IRF5 with Behcet’s disease. Mol Vis 15: 2018-2021. PubMed: 19816589.
- 25. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116: 87-93. doi:10.1016/j.ophtha.2008.09.034. PubMed: 19118700.
- 26. Valentincic NV, de Groot-Mijnes JD, Kraut A, Korosec P, Hawlina M et al. (2011) Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis 17: 2003-2010. PubMed: 21850175.
- 27. Mackensen F, Jakob E, Springer C, Dobner BC, Wiehler U et al. (2013) Interferon versus Methotrexate in Intermediate Uveitis With Macular Edema: Results of a Randomized Controlled Clinical Trial. Am J Ophthalmol 156: 478-486 e471 doi:10.1016/j.ajo.2013.05.002. PubMed: 23786783.
- 28. Plskova J, Greiner K, Forrester JV (2007) Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144: 55-61. doi:10.1016/j.ajo.2007.03.050. PubMed: 17601428.